Loading clinical trials...
Loading clinical trials...
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)
Conditions
Interventions
Vadadustat
Darbepoetin alfa
Locations
439
United States
Research Site
Huntsville, Alabama, United States
Research Site
Tuscumbia, Alabama, United States
Research Site
Glendale, Arizona, United States
Research Site
Mesa, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Tucson, Arizona, United States
Start Date
December 1, 2015
Primary Completion Date
June 4, 2020
Completion Date
July 31, 2020
Last Updated
June 27, 2022
NCT03050268
NCT07039422
NCT05012111
NCT03520647
NCT04304820
NCT05447442
Lead Sponsor
Akebia Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions